Effect of PEGylation on the Stability of Liposomes During Nebulisation and in Lung Surfactant
The DOI matches its Crossref record.
Abstract
Oral inhalation of anticancer drugs or drug delivery system is a novel therapeutic approach in the treatment of lung cancer and requires formulations which are sufficiently stabile during nebulisation and subsequent interaction with the surfactant lining of the lungs. In this study, we assessed the stability of plain and PEGylated transferrin-conjugated liposomes after nebulisation using two different nebulisers (i.e., air-jet and ultrasonic type). Furthermore, the integrity of the liposomal membranes was assessed after incubation in commercial lung surfactant solutions (Alveofact<snm>®</snm>). All liposomal formulations showed no significant changes in their size after nebulisation, independent of the type of nebuliser or the liposomal formulation, respectively. However, PEGylation was of advantage when it came to interactions between liposomes and the surfactant lining of the lungs. PEGylated liposomes were significantly more stable and retained >80% of their drug load over 48 h, which is more than sufficient time for the drug carriers to be taken up by transferrin receptor over-expressing cancer cells in the lung. In conclusion, PEGylated and plain Tf-conjugated liposomes are stable enough to undergo nebulisation in the course of an inhalational therapy, but PEG-stabilisation results in a higher degree of membrane integrity in lung surfactant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advances in PEGylation of important biotech molecules: delivery aspects
Ryan, S. M., Mantovani, G., Wang, X., Haddleton, D. M., & Brayden, D. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.4.371 · Cited by 323
Ruge, C. A., Kirch, J., & Lehr, C.-M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70072-9 · Cited by 280
Self-citationThe formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123
The tripeptide, GHK, induces programmed cell death in SH-SY5Y neuroblastoma cells
E. Matalka, L. (2012) · Journal of Biotechnology & Biomaterials · doi:10.4172/2155-952x.1000144 · Cited by 12
Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment
Shah, M. R., Imran, M., & Ullah, S. (2019) · Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy · doi:10.1016/b978-0-12-816773-1.00006-7 · Cited by 5
Metadata
- Authors
- Anabousi, S., Kleemann, E., Bakowsky, U., Kissel, T., Schmehl, T., Gessler, T., Seeger, W., Lehr, C.-M., & Ehrhardt, C.
- Venue
- Journal of Nanoscience and Nanotechnology
- Publisher
- American Scientific Publishers
- Published
- 2006-09-01
- Volume
- 6
- Issue
- 9
- Pages
- 3010-3016
- ISSN
- 1533-4880 (ISSN-L)
- OpenAlex
- W2318149311
- Cited by
- 54
- References
- 0
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.